Overcoming Resistance to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma

Overcoming Resistance to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma

Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans, and is now responsible for as many deaths as melanoma. Immunotherapy has changed the therapeutic landscape of advanced CSCC after the FDA approval of anti-PD1 molecules for the treatment of locally advanced and me...

Full description

Bibliographic Details
Main Authors: Natalia García-Sancha, Roberto Corchado-Cobos, Lorena Bellido-Hernández, Concepción Román-Curto, Esther Cardeñoso-Álvarez, Jesús Pérez-Losada, Alberto Orfao, Javier Cañueto
Format: Article
Language:English
Published: MDPI AG 2021-10-01
Series:Cancers
Subjects:
cutaneous squamous cell carcinoma
immunotherapy
anti-PD1
biomarkers
predictive medicine
personalized medicine
Online Access:https://www.mdpi.com/2072-6694/13/20/5134

Internet

https://www.mdpi.com/2072-6694/13/20/5134

Similar Items